title: Nanomedicine approaches to improve cancer immunotherapy.
abstract: Significant advances have been made in the field of cancer immunotherapy by orchestrating the body's immune system to eradicate cancer cells. However, safety and efficacy concerns stemming from the systemic delivery of immunomodulatory compounds limits cancer immunotherapies expansion and application. In this context, nanotechnology presents a number of advantages, such as targeted delivery to immune cells, enhanced clinical outcomes, and reduced adverse events, which may aid in the delivery of cancer vaccines and immunomodulatory agents. With this in mind, a diverse range of nanomaterials with different physicochemical characteristics have been developed to stimulate the immune system and battle cancer. In this review, we will focus on some recent developments and the potential advantages of utilizing nanotechnology within the field of cancer immunotherapy. WIREs Nanomed Nanobiotechnol 2017, 9:e1456. doi: 10.1002/wnan.1456 For further resources related to this article, please visit the WIREs website.
authors.affiliation: Laboratory of Nano- and Translational Medicine, Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, Carolina Institute of Nanomedicine; Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC, USA.|Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Qiu
authors.affiliation: Laboratory of Nano- and Translational Medicine, Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, Carolina Institute of Nanomedicine; Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC, USA.
authors.forename: Yuanzeng
authors.initials: Y
authors.lastname: Min
authors.affiliation: Laboratory of Nano- and Translational Medicine, Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, Carolina Institute of Nanomedicine; Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC, USA.
authors.forename: Zach
authors.initials: Z
authors.lastname: Rodgers
authors.affiliation: Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.|Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou, China.
authors.forename: Longzhen
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Laboratory of Nano- and Translational Medicine, Lineberger Comprehensive Cancer Center, Carolina Center for Cancer Nanotechnology Excellence, Carolina Institute of Nanomedicine; Department of Radiation Oncology, University of North Carolina, Chapel Hill, NC, USA.|Department of Radiation Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, China.
authors.forename: Andrew Z
authors.initials: AZ
authors.lastname: Wang
mesh_terms: D006801:Humans; D007167:Immunotherapy; D050997:Nanomedicine; D053758:Nanoparticles; D009369:Neoplasms / Q000188:drug therapy*